BRUSSELS (Reuters) – The European Commission said on Wednesday it had agreed with U.S. company Gilead the supply of more than 20,000 additional doses of its COVID-19 drug Remdesivir, in a bid to tackle shortages of the medication in European countries.
A spokesman for the EU executive said Brussels had agreed with Gilead last Friday the supply of nearly 20,300 additional doses for the treatment of about 3,400 patients.
It said it had paid 7 million euros ($8.2 million) for the new supply, which is in addition to 30,000 courses of treatment it had bought at the end of July.
($1 = 0.8505 euros)
(Reporting by Francesco Guarascio @fraguarascio and John Chalmers; Editing by Jon Boyle)
